Advancements in Dermatology: A Weekly Review
Dermatologia e Venerologia
Cutting Edge Dermatology: From Alopecia to Hidradenitis
This week we explore groundbreaking dermatology research including new treatments for alopecia areata and hidradenitis suppurativa, insights into chronic hand eczema management, and surprising findings about HPV42's oncogenic potential.
Bibliography
1. Predictors of immunological non-response despite virological suppression in people living with HIV on antiretroviral therapy: A systematic review and meta-analysis.
Authors: Rachman BE, Supranoto YTN, Nurannisa FR, et al.
Journal: PloS one, 2026
PMID: 42862878
DOI: 10.1371/journal.pone.0358793
2. Advantages and limitations of in vitro models for atopic dermatitis: A consensus expert opinion.
Authors: Peters RHW, Smits JPH, van den Bogaard EH, et al.
Journal: The Journal of investigative dermatology, 2026 Oct
PMID: 42246919
DOI: 10.1016/j.jid.2026.04.032
3. IL-13 and skin fibrosis in inflammatory skin diseases.
Authors: Ikegawa N, Nguyen TM, Saito-Sasaki N, et al.
Journal: Frontiers in immunology, 2026
PMID: 42851899
DOI: 10.3389/fimmu.2026.1974049
4. HPV42 - a human papillomavirus classified as a low-risk type with oncogenic potential.
Authors: Burmann SN, Wieland U, Silling S, et al.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2026 Oct
PMID: 41047841
DOI: 10.1111/ddg.15981
5. The Gut Microbiome as a Therapeutic Target in Alopecia Areata: Not Yet Part of the Patient Treatment Plan.
Authors: McMullen E, Hafeez DA, Pai N, et al.
Journal: International journal of dermatology, 2026 Oct
PMID: 41999025
DOI: 10.1111/ijd.70437
6. The Role of Tissue Resident Memory Cells in Immunodermatological Disorders.
Authors: De A, Chakraborty D, Desai S, et al.
Journal: International journal of dermatology, 2026 Oct
PMID: 42473984
DOI: 10.1111/ijd.70594
7. Targeting an IL-17/IL-36 pathogenic hub in hidradenitis suppurativa with a bispecific antibody.
Authors: Sun Y, Mi Z, Yu Y, et al.
Journal: Signal transduction and targeted therapy, 2026 Oct 14
PMID: 42869887
DOI: 10.1038/s41392-026-02886-z
8. Crusted scabies following tralokinumab and systemic corticosteroid treatment for presumed atopic dermatitis.
Authors: Turan TL, Rochín LMC, Blume-Peytavi U, et al.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026 Oct
PMID: 42462997
DOI: 10.1016/j.ijid.2026.108984
9. Efficacy and Safety of Delgocitinib and Its Impact on Patient's Perspective for Moderate-to-severe Chronic Hand Eczema in Adults: A 16-week Real-world Prospective Multicentre Study.
Authors: Pezzolo E, Luyo Saboya RA, Ortoncelli M, et al.
Journal: Acta dermato-venereologica, 2026 Oct 7
PMID: 42839349
DOI: 10.2340/actadv.v106.adv-2026-0765
10. Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.
Authors: Mostaghimi A, Gooderham MJ, Lynde C, et al.
Journal: JAMA dermatology, 2026 Oct 1
PMID: 42584887
DOI: 10.1001/jamadermatol.2026.2853
Authors: Rachman BE, Supranoto YTN, Nurannisa FR, et al.
Journal: PloS one, 2026
PMID: 42862878
DOI: 10.1371/journal.pone.0358793
2. Advantages and limitations of in vitro models for atopic dermatitis: A consensus expert opinion.
Authors: Peters RHW, Smits JPH, van den Bogaard EH, et al.
Journal: The Journal of investigative dermatology, 2026 Oct
PMID: 42246919
DOI: 10.1016/j.jid.2026.04.032
3. IL-13 and skin fibrosis in inflammatory skin diseases.
Authors: Ikegawa N, Nguyen TM, Saito-Sasaki N, et al.
Journal: Frontiers in immunology, 2026
PMID: 42851899
DOI: 10.3389/fimmu.2026.1974049
4. HPV42 - a human papillomavirus classified as a low-risk type with oncogenic potential.
Authors: Burmann SN, Wieland U, Silling S, et al.
Journal: Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2026 Oct
PMID: 41047841
DOI: 10.1111/ddg.15981
5. The Gut Microbiome as a Therapeutic Target in Alopecia Areata: Not Yet Part of the Patient Treatment Plan.
Authors: McMullen E, Hafeez DA, Pai N, et al.
Journal: International journal of dermatology, 2026 Oct
PMID: 41999025
DOI: 10.1111/ijd.70437
6. The Role of Tissue Resident Memory Cells in Immunodermatological Disorders.
Authors: De A, Chakraborty D, Desai S, et al.
Journal: International journal of dermatology, 2026 Oct
PMID: 42473984
DOI: 10.1111/ijd.70594
7. Targeting an IL-17/IL-36 pathogenic hub in hidradenitis suppurativa with a bispecific antibody.
Authors: Sun Y, Mi Z, Yu Y, et al.
Journal: Signal transduction and targeted therapy, 2026 Oct 14
PMID: 42869887
DOI: 10.1038/s41392-026-02886-z
8. Crusted scabies following tralokinumab and systemic corticosteroid treatment for presumed atopic dermatitis.
Authors: Turan TL, Rochín LMC, Blume-Peytavi U, et al.
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026 Oct
PMID: 42462997
DOI: 10.1016/j.ijid.2026.108984
9. Efficacy and Safety of Delgocitinib and Its Impact on Patient's Perspective for Moderate-to-severe Chronic Hand Eczema in Adults: A 16-week Real-world Prospective Multicentre Study.
Authors: Pezzolo E, Luyo Saboya RA, Ortoncelli M, et al.
Journal: Acta dermato-venereologica, 2026 Oct 7
PMID: 42839349
DOI: 10.2340/actadv.v106.adv-2026-0765
10. Upadacitinib for Severe Alopecia Areata in Adults and Adolescents: Two Phase 3 UP-AA Randomized Clinical Trials.
Authors: Mostaghimi A, Gooderham MJ, Lynde C, et al.
Journal: JAMA dermatology, 2026 Oct 1
PMID: 42584887
DOI: 10.1001/jamadermatol.2026.2853
